FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200023482> ?p ?o ?g. }

• W4200023482 endingPage "e2139351" @default.
• W4200023482 startingPage "e2139351" @default.
• W4200023482 abstract "Mass azithromycin distributions may decrease childhood mortality, although the causal pathway is unclear. The potential for antibiotics to function as growth promoters may explain some of the mortality benefit.To investigate whether biannual mass azithromycin distributions are associated with increased childhood growth.This cluster-randomized trial was performed from December 2014 until March 2020 among 30 rural communities in Boboye and Loga departments in Niger, Africa, with populations from 200 to 2000 individuals. Communities were randomized in a 1:1 ratio to biannual mass distributions of azithromycin or placebo for children ages 1 to 59 months. Participants, field-workers, and study personnel were masked to treatment allocation. Height and weight changes from baseline to follow-up at 4 years were compared between groups. Data were analyzed from June through November 2021.Participants received azithromycin at 20 mg/kg using height-based approximation or by weight for children unable to stand every 6 months at the participants' households. Placebo contained the vehicle of the azithromycin suspension.Longitudinal anthropometric assessments were performed on a random sample of children before the first treatment and then annually for 5 years. Height and weight were the prespecified primary outcomes.Among 3936 children enrolled from 30 communities, baseline characteristics were similar between 1299 children in the azithromycin group and 2637 children in the placebo group (mean 48.2% [95% CI, 45.5% to 50.8%] girls vs 48.0% [95% CI, 45.7% to 50.3%] girls; mean age, 30.8 months [95% CI, 29.5 to 32.0 months] vs 30.6 months [95% CI, 29.2 to 31.6 months]). Baseline anthropometric assessments were performed among 2230 children, including 985 children in the azithromycin group and 1245 children in the placebo group, of whom follow-up measurements were available for 789 children (80.1%) and 1063 children (85.4%), respectively. At the prespecified 4-year follow-up visit, children in the azithromycin group gained a mean 6.7 cm (95% CI, 6.5 to 6.8 cm) in height and 1.7 kg (95% CI, 1.7 to 1.8 kg) in weight per year and children in the placebo group gained a mean 6.6 cm (95% CI, 6.4 to 6.7 cm) in height and 1.7 kg (95% CI, 1.7 to 1.8 kg) in weight per year. Height at 4 years was not statistically significantly different between groups when adjusted for baseline height (0.08 cm [95% CI, -0.12 to 0.28 cm] greater in the azithromycin group; P = .45), and neither was weight when adjusted for height and baseline weight (0.02 kg [95% CI, -0.10 to 0.06 kg] less in the azithromycin group; P = .64). However, among children in the shortest quartile of baseline height, azithromycin was associated with a 0.4 cm (95% CI, 0.1 to 0.7 cm) increase in height compared with placebo.This study did not find evidence of an association between mass azithromycin distributions and childhood growth, although subgroup analysis suggested some benefit for the shortest children. These findings suggest that the mortality benefit of mass azithromycin distributions is unlikely to be due solely to growth promotion.ClinicalTrials.gov Identifier: NCT02048007." @default.
• W4200023482 created "2021-12-31" @default.
• W4200023482 creator A5004723861 @default.
• W4200023482 creator A5006338001 @default.
• W4200023482 creator A5008225585 @default.
• W4200023482 creator A5009715006 @default.
• W4200023482 creator A5011903635 @default.
• W4200023482 creator A5013426972 @default.
• W4200023482 creator A5015714457 @default.
• W4200023482 creator A5015879639 @default.
• W4200023482 creator A5017144415 @default.
• W4200023482 creator A5021420755 @default.
• W4200023482 creator A5024510654 @default.
• W4200023482 creator A5028036366 @default.
• W4200023482 creator A5030170309 @default.
• W4200023482 creator A5033288392 @default.
• W4200023482 creator A5035723806 @default.
• W4200023482 creator A5038025520 @default.
• W4200023482 creator A5044569537 @default.
• W4200023482 creator A5045329599 @default.
• W4200023482 creator A5049197682 @default.
• W4200023482 creator A5050843283 @default.
• W4200023482 creator A5052072975 @default.
• W4200023482 creator A5053637474 @default.
• W4200023482 creator A5056385766 @default.
• W4200023482 creator A5058005277 @default.
• W4200023482 creator A5068761394 @default.
• W4200023482 creator A5069369290 @default.
• W4200023482 creator A5070363052 @default.
• W4200023482 creator A5071963296 @default.
• W4200023482 creator A5073089221 @default.
• W4200023482 creator A5073387693 @default.
• W4200023482 creator A5075952432 @default.
• W4200023482 creator A5077631479 @default.
• W4200023482 creator A5080095497 @default.
• W4200023482 creator A5081280153 @default.
• W4200023482 creator A5081678518 @default.
• W4200023482 creator A5083161710 @default.
• W4200023482 creator A5087875655 @default.
• W4200023482 creator A5088127746 @default.
• W4200023482 creator A5088225687 @default.
• W4200023482 creator A5088956928 @default.
• W4200023482 creator A5089206390 @default.
• W4200023482 creator A5089608584 @default.
• W4200023482 creator A5089886673 @default.
• W4200023482 creator A5090465311 @default.
• W4200023482 creator A5091689131 @default.
• W4200023482 creator A5091803660 @default.
• W4200023482 creator A9999999999 @default.
• W4200023482 date "2021-12-30" @default.
• W4200023482 modified "2023-10-03" @default.
• W4200023482 title "Effect of Mass Azithromycin Distributions on Childhood Growth in Niger" @default.
• W4200023482 cites W1489840582 @default.
• W4200023482 cites W1987018399 @default.
• W4200023482 cites W1991706608 @default.
• W4200023482 cites W1997468521 @default.
• W4200023482 cites W2047367008 @default.
• W4200023482 cites W2061525364 @default.
• W4200023482 cites W2073582268 @default.
• W4200023482 cites W2107031129 @default.
• W4200023482 cites W2117086741 @default.
• W4200023482 cites W2136998290 @default.
• W4200023482 cites W2137247340 @default.
• W4200023482 cites W2142949420 @default.
• W4200023482 cites W2151438209 @default.
• W4200023482 cites W2162881343 @default.
• W4200023482 cites W2410027104 @default.
• W4200023482 cites W2609152998 @default.
• W4200023482 cites W2794770411 @default.
• W4200023482 cites W2801239041 @default.
• W4200023482 cites W2901408395 @default.
• W4200023482 cites W2948281912 @default.
• W4200023482 cites W2948859714 @default.
• W4200023482 cites W2953394580 @default.
• W4200023482 cites W3001897482 @default.
• W4200023482 cites W3034749509 @default.
• W4200023482 cites W3100227291 @default.
• W4200023482 cites W3137386255 @default.
• W4200023482 cites W2992049275 @default.
• W4200023482 doi "https://doi.org/10.1001/jamanetworkopen.2021.39351" @default.
• W4200023482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34967883" @default.
• W4200023482 hasPublicationYear "2021" @default.
• W4200023482 type Work @default.
• W4200023482 citedByCount "3" @default.
• W4200023482 countsByYear W42000234822022 @default.
• W4200023482 countsByYear W42000234822023 @default.
• W4200023482 crossrefType "journal-article" @default.
• W4200023482 hasAuthorship W4200023482A5004723861 @default.
• W4200023482 hasAuthorship W4200023482A5006338001 @default.
• W4200023482 hasAuthorship W4200023482A5008225585 @default.
• W4200023482 hasAuthorship W4200023482A5009715006 @default.
• W4200023482 hasAuthorship W4200023482A5011903635 @default.
• W4200023482 hasAuthorship W4200023482A5013426972 @default.
• W4200023482 hasAuthorship W4200023482A5015714457 @default.
• W4200023482 hasAuthorship W4200023482A5015879639 @default.
• W4200023482 hasAuthorship W4200023482A5017144415 @default.
• W4200023482 hasAuthorship W4200023482A5021420755 @default.
• W4200023482 hasAuthorship W4200023482A5024510654 @default.

• next